
    
      This study is a Phase II study designed to evaluate the toxicity profile for oxaliplatin and
      docetaxel and to determine the response rate to this study drug combination. The primary
      objective of the study is response rate by RECIST criteria. The secondary objective is time
      to progression, duration of response, and toxicity. Patients will receive:

        -  oxaliplatin 85mg/m2 over 2 hours on Days 1 and 15

        -  docetaxel 30mg/m2 on Days 1 and 8

      Cycles are to be repeated every 28 days for a maximum of 6 cycles.
    
  